{
    "2020-11-02": [
        [
            {
                "time": "",
                "original_text": "刘格菘第二！年内四只翻倍基金，他竟独占其三",
                "features": {
                    "keywords": [
                        "刘格菘",
                        "基金",
                        "翻倍"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "基金"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "迈瑞、恒瑞、泰格、石药、华兰生物……上市药企投资价值大PK，你最PICK谁？",
                "features": {
                    "keywords": [
                        "迈瑞",
                        "恒瑞",
                        "泰格",
                        "石药",
                        "华兰生物",
                        "投资价值"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[公司]从疫情影恢复明显 泰格医药前三季度净利同比增长149.57%至13.18亿元",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "疫情恢复",
                        "净利增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "美银证券：荐买入泰格医药(03347) 大升目标价至150港元",
                "features": {
                    "keywords": [
                        "美银证券",
                        "泰格医药",
                        "买入",
                        "目标价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药(03347.HK)获NETYONEUKLIMITED增持12.05万股",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "增持",
                        "NETYONEUKLIMITED"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "疫情影响逐渐消退，关注高成长龙头+细分冠军 -- 医药生物上市公司2020年三季报小结",
                "features": {
                    "keywords": [
                        "疫情影响",
                        "高成长龙头",
                        "细分冠军",
                        "医药生物",
                        "三季报"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【浙商医药|三季报】创新药研发高景气有望持续，看好CDMO业绩加速",
                "features": {
                    "keywords": [
                        "浙商医药",
                        "三季报",
                        "创新药",
                        "CDMO",
                        "业绩加速"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}